Tough comps in Q4e but tailwinds into 2024e Cost reductions to yield margin expansion ahead Share at...
Q-linea has announced a SEK 50m OPEX reduction ahead of the announced CEO change in 2024.
Redeye leaves its comments on Nanologica following today’s news that it has announced a fully guaran...
Redeye leaves a comment following Alzinova’s announcement of a completed primary analysis of the pha...
Redeye is encouraged to learn that Lipum’s lead candidate, SOL-116, has shown favorable safety and t...
SRV will release its Q4 results on Feb 1; we expect revenue to turn to growth with ongoing business ...
Redeye increases its base case after the positive topline results from OPTIMIZE-1, the phase II stud...
Ahead of NoHo's Q4 report, due on 15 February, we adjust our estimates to reflect the guidance updat...
Redeye comments on last week’s news from Apple, where it announced changes to iOS and the App Store ...
We cut '23e-'25e adj. EBITA by 13-10% Inflation data for Q4 suggest negative-to-neutral volume/mix T...
Good organic growth but weak margins in Q4 2024 will be a year of transition EBITDA revised down 8-1...
Q4e: Tuesday, 30 January at 8:00 CET Healthy 2024 with 6% organic growth and solid margin expansion ...
Redeye provides its comments on Scandinavian ChemoTech’s press release from earlier today.
DT reports Q4 on Feb 1. MBU may not grow much this year, yet organic SBU-driven recovery and recent ...
Svagare marknad ger avtryck i orderingången… Även om kundaktiviteten är fortsatt intensiv och den un...
Rapportkommentar Diamyds rapport för det första kvartalet 2023/2024 var i linje med våra förväntning...
Redeye comments on Ependion's Q4 2023 report, which came in slightly below on the sales level and, a...
Redeye updates our outlook after Q4 2023. XVIVO delivers improved gross margins with a softer organi...
This afternoon after market close, BankNordik issued its 2024 net profit guidance of DKK 225-255m, s...
EcoRub har idag publicerat bolagets Q4-rapport och visar på fortsatta framsteg.